Literature DB >> 33092426

Tumor Necrosis Factor-alpha (TNF-α) -238 G/A Polymorphism Is Associated with the Treatment Resistance and Attempted Suicide in Schizophrenia.

Hasan Mervan Aytac1, Kursat Ozdilli2, Fatima Ceren Tuncel3, Mustafa Pehlivan4, Sacide Pehlivan3.   

Abstract

Abnormality of the immune system may play an important role in the pathogenesis of schizophrenia (SCZ). We aim to investigate the relationship between clinical features of SCZ and tumor necrosis factor-alpha (TNF-α) -238 G/A, -308 G/A polymorphisms in SCZ patients by comparing genotype distributions of TNF-α gene polymorphisms between patients and healthy controls. A sample of 113 patients with SCZ and 104 healthy volunteers was included in the study. SCID-I was used to confirming the diagnosis according to DSM-IV-TR criteria. We evaluated the patients with some scales and data forms in terms of clinical features, symptom severity, level of insight, suicidal behavior, and treatment response. PCR-RFLP was used to determine TNF-α gene polymorphisms from DNA material. The distributions of TNF-α - 238 G/A and TNF-α - 308 G/A polymorphisms of the patients diagnosed with SCZ were not significantly different from the control group. There was a significant difference in the TNF-α - 238 G/A genotype distributions between treatment-resistant and treatment-responsive SCZ patients. Again, the distributions of TNF-α - 238 G/A genotype of attempted suicide patients in SCZ were significantly different from the non-attempted suicide of SCZ patients. Whereas TNF-α - 238 G/A and -308 G/A polymorphisms were not associated with SCZ, TNF-α - 238 G/A polymorphism may be related to treatment resistance and attempted suicide in SCZ patients in the Turkish population.

Entities:  

Keywords:  Schizophrenia; attempted suicide; single nucleotide polymorphism; tnf-α; treatment resistance

Mesh:

Substances:

Year:  2020        PMID: 33092426     DOI: 10.1080/08820139.2020.1832115

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

1.  Quantitative detection of methylated SOCS-1 in schizophrenia and bipolar disorder considering SOCS-1 -1478CA/del polymorphism and clinical parameters.

Authors:  Hasan Mervan Aytac; Sacide Pehlivan; Mustafa Pehlivan; Yasemin Oyaci
Journal:  Ir J Med Sci       Date:  2022-05-20       Impact factor: 1.568

2.  Investigation of inflammation related gene polymorphism of the mannose-binding lectin 2 in schizophrenia and bipolar disorder.

Authors:  Hasan M Aytac; Menekse S Yazar; Ayse Erol; Sacide Pehlivan
Journal:  Neurosciences (Riyadh)       Date:  2021-10       Impact factor: 0.735

Review 3.  Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review.

Authors:  Andrea de Bartolomeis; Annarita Barone; Licia Vellucci; Benedetta Mazza; Mark C Austin; Felice Iasevoli; Mariateresa Ciccarelli
Journal:  Mol Neurobiol       Date:  2022-08-13       Impact factor: 5.682

Review 4.  Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia.

Authors:  Natalia A Shnayder; Aiperi K Khasanova; Anna I Strelnik; Mustafa Al-Zamil; Andrey P Otmakhov; Nikolay G Neznanov; German A Shipulin; Marina M Petrova; Natalia P Garganeeva; Regina F Nasyrova
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.